Development
BioXcel Therapeutics, Inc.
BTAI
$1.84
$0.3120.26%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -20.76% | -42.06% | -67.76% | -109.79% | -55.93% |
| Total Depreciation and Amortization | -7.06% | -3.57% | 3.90% | 6.58% | 10.39% |
| Total Amortization of Deferred Charges | 73.73% | 10.90% | -- | -- | -- |
| Total Other Non-Cash Items | -8.03% | 33.11% | 43.31% | 106.53% | -0.79% |
| Change in Net Operating Assets | 46.43% | 2,378.29% | -12.98% | 187.25% | 238.34% |
| Cash from Operations | -20.52% | -15.42% | -61.52% | -93.85% | -54.39% |
| Capital Expenditure | -- | -5.26% | -- | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -5.26% | -- | 100.00% | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | 35.14% | -- | -- | -32.39% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -- | -- | -- |
| Cash from Financing | -100.00% | -99.62% | -- | -- | 42,221.13% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3,202.64% | -215.02% | 13.31% | -93.49% | 94.35% |